Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;60(1):24-29.
doi: 10.3345/kjp.2017.60.1.24. Epub 2017 Jan 24.

The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers

Jae Won Yoo  1 , Ji Mok Kim  1 , Hong Ryang Kil  1
Affiliations

The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers

Jae Won Yoo et al. Korean J Pediatr. 2017 Jan.

Abstract

Purpose: Previously, Kawasaki disease (KD) treatment with low-dose aspirin was administered for 6-8 weeks after the acute phase. However, inflammatory marker levels normalize before 6-8 weeks. In this study, we aimed to investigate the clinical outcome of short-term low-dose aspirin treatment based on inflammatory and thrombotic marker levels.

Methods: We performed a retrospective review of the medical records of patients with KD who were hospitalized at Chungnam National University Hospital between September 2012 and May 2014. When fever subsided, low-dose aspirin treatment was started. Inflammatory (white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) and thrombotic markers (D-dimer) were monitored at follow-ups conducted in 1- to 2-week intervals. The low-dose aspirin administration was terminated when both markers were normalized and no cardiovascular complications were observed.

Results: Eighty-four patients with KD (complete KD, n=49; incomplete KD, n=35) were enrolled. The inflammatory and thrombotic marker levels were normalized within 3-4 weeks on average. At the beginning the low-dose aspirin treatment, 9 patients had coronary artery lesions but 75 did not. When the low-dose aspirin administration was terminated at the time the inflammatory marker levels were normalized, no new CALs developed during the follow-up at 6-8 weeks.

Conclusion: Most of the inflammatory marker levels were normalized within 3-4 weeks after the acute phase of KD. New cardiovascular complications did not develop during the course of the short-term aspirin treatment based on the inflammatory marker levels, clinical findings, and echocardiography.

Keywords: Aspirin; Inflammation; Kawasaki disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. The cardiovascular outcome of short-term low-dose aspirin treatment. KD, Kawasaki disease; CAL, coronary artery lesion; D/C, discharge.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Acetylsalicylic acid for children with Kawasaki disease.
    Sakulchit T, Benseler SM, Goldman RD. Sakulchit T, et al. Can Fam Physician. 2017 Aug;63(8):607-609. Can Fam Physician. 2017. PMID: 28807954 Free PMC article. Review.
  • [Pediatric expert consensus on the application of aspirin in Kawasaki disease].
    Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital; Children's Hospital of Shanghai Jiao Tong University; Beijing Children's Hospital of Capital Medical University; Shengjing Hospital of China Medical University; Affiliated Hospital of Yan'an University; Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association; General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor Association; Shanghai Cooperation Organization Hospital Cooperation Alliance; Pediatric International Exchange and Cooperation Center; Editorial Board of Chinese Journal of Contemporary Pediatrics. Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):597-603. doi: 10.7499/j.issn.1008-8830.2203190. Zhongguo Dang Dai Er Ke Za Zhi. 2022. PMID: 35652428 Free PMC article. Chinese.
  • L’acide acétylsalicylique pour les enfants atteints de la maladie de Kawasaki.
    Sakulchit T, Benseler SM, Goldman RD. Sakulchit T, et al. Can Fam Physician. 2017 Aug;63(8):e359-e362. Can Fam Physician. 2017. PMID: 28807967 Free PMC article. French.

References

    1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–1733. - PubMed
    1. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J. 2014;78:2521–2562. - PubMed
    1. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J. 2014;33:24–27. - PubMed
    1. Kang HJ, Kim GN, Kil HR. Changes of clinical characteristics and outcomes in patients with Kawasaki disease over the past 7 years in a single center study. Korean J Pediatr. 2013;56:389–395. - PMC - PubMed
    1. Akagi T, Kato H, Inoue O, Sato N. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr. 1991;150:642–646. - PubMed

LinkOut - more resources